Case Studies
January 6, 2026
In this use case, find out how MMIT, using NorstellaLinQ, helped one manufacturer improve disease-state education and guide more effective account-level targeting by isolating specific patient cohorts with structured and unstructured EMR data.
Webinars
November 14, 2025
In this webinar, learn how pharma companies can mitigate the most common risks associated with launch, from overestimating a brand’s adoption peak to underestimating the necessary contracting spend. Our experts explain the concrete steps your brand team can take in advance —so you can launch your therapy without fear of failure.
Case Studies
November 3, 2025
In this use case, learn how one pharma company uses real-world data triggers about patient-level events to improve sales prioritization and pull-through.
Infographics
November 3, 2025
Learn how pharma and healthcare IT companies can determine coverage details for individual patients with MMIT’s Bridging as a Service and Coverage API. This infographic shows how prescription BIN/PCN/Group (BPG) data serves as the anchor key to unlock coverage clarity.
Case Studies
November 3, 2025
In this use case, learn how one pharma company used coverage data plus real-world data signals from claims, labs, and EMR systems to better understand the connection between payer coverage and claims. After identifying missing billing codes as the primary driver of denials, the company launched an HCP education campaign to help resolve the access […]
Case Studies
August 2, 2023
A pharma company with several approved brands with large market share was developing a new Crohn’s disease drug. The company partnered with MMIT to determine whether the new drug would be approved in the marketplace and how it would perform.
P&T Sessions
November 29, 2021
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Sessions
May 19, 2021
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
